Merck winds down TIGIT, LAG-3 programs meant to temper Keytruda erosion

After multiple clinical failures, it’s finally the end of the road for Merck’s TIGIT program. The company is dropping development of its anti-TIGIT candidate vibostolimab after two more Phase 3 studies of a fixed-dose combination ...